Compare Stocks → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:APTXNYSE:LCINASDAQ:LXRXNASDAQ:RTTRNASDAQ:XOMA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPTXAptinyx$0.10+3.1%$0.08$0.01▼$0.72N/A1.271.32 million shs231,100 shsLCILannett$1.54$0.64▼$3.72$7.38M0.9592,067 shs280,600 shsLXRXLexicon Pharmaceuticals$2.40+9.6%$2.31$0.92▼$3.79$590.98M1.285.01 million shs7.06 million shsRTTRRitter Pharmaceuticals$0.40$2.99$0.15▼$1.27$18.46M-0.4314.23 million shs79,811 shsXOMAXOMA$24.05+3.0%$22.88$13.48▼$26.83$279.61M0.5820,361 shs19,834 shs10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPTXAptinyx0.00%0.00%0.00%0.00%-29.36%LCILannett0.00%0.00%0.00%0.00%-56.06%LXRXLexicon Pharmaceuticals+9.59%-0.41%-8.40%+56.86%+1.27%RTTRRitter Pharmaceuticals0.00%+8.75%-18.40%-27.60%-55.57%XOMAXOMA+3.04%-1.96%-1.27%+30.00%+8.19%Did You Get Your Free Bitcoin Yet? (Ad)And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right hereMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPTXAptinyxN/AN/AN/AN/AN/AN/AN/AN/ALCILannettN/AN/AN/AN/AN/AN/AN/AN/ALXRXLexicon Pharmaceuticals0.4769 of 5 stars2.01.00.00.01.91.70.6RTTRRitter PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AXOMAXOMA4.0708 of 5 stars3.53.00.03.02.81.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPTXAptinyxN/AN/AN/AN/ALCILannettN/AN/AN/AN/ALXRXLexicon PharmaceuticalsN/AN/A$5.00108.33% UpsideRTTRRitter PharmaceuticalsN/AN/AN/AN/AXOMAXOMA3.00Buy$74.00207.69% UpsideCurrent Analyst RatingsLatest LXRX, RTTR, APTX, XOMA, and LCI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/16/2024XOMAXOMAHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$74.00(Data available from 3/29/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPTXAptinyx$1MN/AN/AN/A$0.57 per shareN/ALCILannett$340.58M0.00N/AN/A($23.34) per share0.00LXRXLexicon Pharmaceuticals$1.20M492.48N/AN/A$0.62 per share3.87RTTRRitter PharmaceuticalsN/AN/AN/AN/A$0.10 per shareN/AXOMAXOMA$4.76M58.77N/AN/A$7.72 per share3.12Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPTXAptinyx-$64.85M-$0.98N/AN/AN/AN/AN/AN/AN/ALCILannett-$231.62M-$18.88N/AN/AN/A-62.40%N/A-13.39%N/ALXRXLexicon Pharmaceuticals-$175.61M-$0.80N/AN/AN/A-14,573.20%-138.54%-71.29%5/7/2024 (Estimated)RTTRRitter Pharmaceuticals-$10.13MN/AN/A∞N/AN/AN/A-162.05%N/AXOMAXOMA-$40.83M-$4.04N/AN/AN/A-886.91%-25.17%-17.08%5/14/2024 (Estimated)Latest LXRX, RTTR, APTX, XOMA, and LCI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/8/2024Q4 2023XOMAXOMA-$0.36-$0.49-$0.13$0.89$1.01 million$1.83 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPTXAptinyxN/AN/AN/AN/AN/ALCILannettN/AN/AN/AN/AN/ALXRXLexicon PharmaceuticalsN/AN/AN/AN/AN/ARTTRRitter PharmaceuticalsN/AN/AN/AN/AN/AXOMAXOMAN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPTXAptinyxN/AN/AN/ALCILannettN/A2.231.39LXRXLexicon Pharmaceuticals1.075.606.91RTTRRitter PharmaceuticalsN/A3.673.67XOMAXOMA1.348.688.68OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPTXAptinyxN/ALCILannett40.28%LXRXLexicon Pharmaceuticals74.70%RTTRRitter Pharmaceuticals0.84%XOMAXOMA95.92%Insider OwnershipCompanyInsider OwnershipAPTXAptinyx10.97%LCILannett13.12%LXRXLexicon Pharmaceuticals6.80%RTTRRitter Pharmaceuticals15.40%XOMAXOMA5.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAPTXAptinyx12N/AN/ANot OptionableLCILannett81010.77 million9.35 millionOptionableLXRXLexicon Pharmaceuticals135246.24 million229.49 millionOptionableRTTRRitter Pharmaceuticals746.15 millionN/ANot OptionableXOMAXOMA1311.63 million11.02 millionOptionableLXRX, RTTR, APTX, XOMA, and LCI HeadlinesSourceHeadlineXOMA (NASDAQ:XOMA) Shares Cross Above Two Hundred Day Moving Average of $18.73americanbankingnews.com - March 23 at 2:56 AMXOMA Declares Quarterly Preferred Stock Dividendsglobenewswire.com - March 21 at 7:30 AMXOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.globenewswire.com - March 19 at 4:05 PMKINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTEbusinesswire.com - March 13 at 11:49 AMXOMA Stock Earnings: XOMA Misses EPS, Misses Revenue for Q4 2023investorplace.com - March 8 at 1:03 PMXOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Valuefinance.yahoo.com - March 8 at 7:51 AMXOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Valueglobenewswire.com - March 8 at 7:30 AMXOMA to Present at Upcoming Investor Conferences in Marchglobenewswire.com - February 28 at 7:30 AMKINNATE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTEbusinesswire.com - February 19 at 11:03 AMCompare with Maple Leaf Green World Inc (4HV0)msn.com - February 18 at 12:30 PMXOMA to acquire Kinnate Biopharmathepharmaletter.com - February 17 at 10:21 AMXOMA Mar 2024 20.000 putfinance.yahoo.com - February 17 at 10:21 AMXOMA Jun 2024 25.000 callfinance.yahoo.com - February 17 at 10:21 AMBiotech Royalty Aggregator XOMA To Acquire Small Cancer-Drug Developer Kinnate Biopharmabenzinga.com - February 16 at 1:37 PMXOMA Agrees to Acquire Kinnate Biopharmamarketwatch.com - February 16 at 8:36 AMXOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Rightfinance.yahoo.com - February 16 at 8:36 AMXOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Rightfinance.yahoo.com - February 16 at 8:36 AMXOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Rightglobenewswire.com - February 16 at 8:00 AMWith 37% ownership, XOMA Corporation (NASDAQ:XOMA) has piqued the interest of institutional investorsfinance.yahoo.com - January 20 at 2:06 PMXOMA To Pay $1 Mln Milestone To LadRx As FDA Accepts Zevra's Arimoclomol NDA For NPCmarkets.businessinsider.com - January 11 at 10:48 PMFDA Acceptance of Zevra's Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRxtmcnet.com - January 11 at 5:46 PMXoma to Make $1M Milestone Payment to LadRx After FDA Accepts Zevra Application for Arimoclomolmarketwatch.com - January 11 at 5:46 PMXoma To Make $1 Mln Milestone Payment To LadRx After FDA Accepts Zevra's NDA For Arimoclomolmarkets.businessinsider.com - January 11 at 5:46 PMFDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRxfinance.yahoo.com - January 11 at 5:46 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAptinyxNASDAQ:APTXAptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.LannettNYSE:LCILannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. It offers products in different forms including capsules, tablets, liquids, powders, and sprays. The company was founded in 1942 and is headquartered in Trevose, PA.Lexicon PharmaceuticalsNASDAQ:LXRXLexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.Ritter PharmaceuticalsNASDAQ:RTTRRitter Pharmaceuticals, Inc. develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California.XOMANASDAQ:XOMAXOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.